Drug Approval | February 16, 2026
Nucala is the first and only monthly biologic in the EU evaluated in a wide COPD population with an eosinophilic phenotype
The current two-vial format requires healthcare professionals to mix a lyophilised antigen with a liquid adjuvant before administration
This drug candidate, which is currently progressing through pivotal clinical studies, has the potential to become the first add-on therapy for schizophrenia patients who do not respond adequately
The accelerated review covers WCK 5222 for multiple critical infections
The trial will evaluate the efficacy and safety of IPX203 versus immediate-release levodopa/carbidopa
The approval follows strong results from Roche’s phase II NOBILITY and phase III REGENCY studies
Angelini Ventures has already invested €125 million in 22 startups
Gobivaz is authorised for adults with rheumatoid arthritis (in combination with methotrexate), psoriatic arthritis (with or without methotrexate), axial spondyloarthritis, and ulcerative colitis
The new algorithm will be introduced as part of Roche’s CKD Algorithm Panelon thenavify Algorithm Suite
Subscribe To Our Newsletter & Stay Updated
